Jagsonpal Pharmaceuticals Limited

BSE:507789 Stock Report

Market Cap: ₹16.2b

Jagsonpal Pharmaceuticals Past Earnings Performance

Past criteria checks 5/6

Jagsonpal Pharmaceuticals has been growing earnings at an average annual rate of 22.8%, while the Pharmaceuticals industry saw earnings growing at 13.7% annually. Revenues have been growing at an average rate of 7.5% per year. Jagsonpal Pharmaceuticals's return on equity is 26.5%, and it has net margins of 20.6%.

Key information

22.8%

Earnings growth rate

22.4%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate7.5%
Return on equity26.5%
Net Margin20.6%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Jagsonpal Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:507789 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 242,5365238330
30 Sep 242,2692437950
30 Jun 242,1002036110
31 Mar 242,0872257730
31 Dec 232,2072458280
30 Sep 232,3362838670
30 Jun 232,3633136820
31 Mar 232,3672678200
31 Dec 222,4102237670
30 Sep 222,3481987360
30 Jun 222,3261315820
31 Mar 222,1761897040
31 Dec 212,1682476890
30 Sep 212,1942476910
30 Jun 212,1632145650
31 Mar 211,8791716590
31 Dec 201,7461355500
30 Sep 201,5951045430
30 Jun 201,450844900
31 Mar 201,586796870
31 Dec 191,675935250
30 Sep 191,673885060
30 Jun 191,697854910
31 Mar 191,668724830
31 Dec 181,611304840
30 Sep 181,573-104600
30 Jun 181,421-664440
31 Mar 181,266-1164340
31 Dec 171,234-954250
30 Sep 171,193264180
30 Jun 171,305703940
01 Apr 171,4411194240
31 Dec 161,5341314350
30 Sep 161,537354310
30 Jun 161,466344080
31 Mar 161,435333970
31 Dec 151,434135640
30 Sep 151,412105460
30 Jun 151,41293140
31 Mar 151,382123340
31 Dec 141,306235680
30 Sep 141,359325850
30 Jun 141,397284680
31 Mar 141,439216050

Quality Earnings: 507789 has a large one-off gain of ₹199.0M impacting its last 12 months of financial results to 31st December, 2024.

Growing Profit Margin: 507789's current net profit margins (20.6%) are higher than last year (11.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 507789's earnings have grown significantly by 22.8% per year over the past 5 years.

Accelerating Growth: 507789's earnings growth over the past year (113.4%) exceeds its 5-year average (22.8% per year).

Earnings vs Industry: 507789 earnings growth over the past year (113.4%) exceeded the Pharmaceuticals industry 21.2%.

Return on Equity

High ROE: 507789's Return on Equity (26.5%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/24 23:33
End of Day Share Price 2025/01/24 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jagsonpal Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution